SURMOUNT-5

Definition

The phase 3b head-to-head trial comparing tirzepatide (Zepbound) to semaglutide (Wegovy) for chronic weight management in non-diabetic adults with obesity. Aronne and colleagues (NEJM 2025, PMID 40353578) reported tirzepatide -20.2% body weight versus semaglutide -13.7% at 72 weeks — a 6.5-percentage-point advantage for tirzepatide.

SURMOUNT-5 trial deep-dive →

Definition curated by Weight Loss Rankings — sourced from FDA labels and peer-reviewed PubMed literature, never AI-generated summaries.

Related terms in trial

• SURMOUNT-2
• SURMOUNT-3
• SURPASS-2
• SUSTAIN-6
• REWIND
• PIONEER 6
• STEP-HFpEF
• EXSCEL
• ELIXA
• AMPLITUDE-O
• HARMONY OUTCOMES
• SCALE Diabetes
• STEP 2
• SUMMIT
• SCALE Maintenance

Looking for more depth?

• SURMOUNT-5 trial deep-dive
• Browse the full GLP-1 glossary (124 terms across 8 categories)
• Research articles — primary-source deep dives
• Tools and calculators
• Compare GLP-1 telehealth providers